Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enzo Biochem (ENZ) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 329,120
  • Shares Outstanding, K 46,280
  • Annual Sales, $ 102,770 K
  • Annual Income, $ 45,290 K
  • 36-Month Beta 1.45
  • Price/Sales 3.20
  • Price/Book 3.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.69 +1.64%
on 12/21/16
7.25 -6.21%
on 01/04/17
+0.01 (+0.15%)
since 12/19/16
3-Month
5.79 +17.44%
on 11/03/16
7.51 -9.45%
on 12/09/16
+0.62 (+10.03%)
since 10/19/16
52-Week
4.00 +70.00%
on 03/04/16
7.51 -9.45%
on 12/09/16
+2.18 (+47.19%)
since 01/19/16

Most Recent Stories

More News
Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter

Mallinckrodt plc (MNK), will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter???s investigation into the acquisition of Synacthen Depot by its Questcor...

Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment....

Allergan's Uterine Fibroids Candidate Positive in Phase III

Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding...

Concert Offers Update on Cystic Fibrosis Drug, Stock Down

Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.

Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of...

Jazz Begins Phase III Study for Label Expansion of Defitelio

Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease....

Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit

Biogen Inc. (BIIB) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP) with respect to an ongoing patent dispute for Tecfidera.

Biogen (BIIB) Presents Positive Phase III Data on Spinraza

Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).

Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo

Eli Lilly and Company (LLY) and Merck & Co., Inc. (MRK) expanded their existing immuno-oncology partnership to include a new study that will evaluate Lilly???s Lartruvo in combination with Merck???s Keytruda...

Amgen: Phase III Data on Hyperparathyroidism Drug Published

Amgen Inc. (AMGN) announced that data from three phase III studies on its pipeline candidate, Parsabiv (etelcalcetide), were published in the Journal of the American Medical Association (JAMA).

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo...

See More

Support & Resistance

2nd Resistance Point 7.04
1st Resistance Point 6.92
Last Price 6.80
1st Support Level 6.72
2nd Support Level 6.64

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.